Segmentation by type categorizes veterinary oncology solutions into five functional sub‑classes, each with a measurable impact on market composition. Chemotherapy agents, such as alkylating drugs and antimetabolites, dominate the therapeutic landscape, reflecting their broad applicability across tumor histologies and contributing the largest revenue portion. Radiation therapy—including external beam and brachytherapy systems—captures a niche yet high‑value segment, driven by advances in precision targeting and equipment miniaturization for veterinary clinics. Surgical interventions, ranging from tumor excision to limb‑sparing procedures, constitute a significant service‑based share, especially in companion‑animal care where curative intent is prevalent. Immunotherapy products, exemplified by cancer vaccines and checkpoint inhibitors, are emerging rapidly, supported by translational insights from human oncology and representing a growing share of innovative spend. Finally, targeted therapy—small‑molecule inhibitors and monoclonal antibodies—addresses molecularly defined cancers, contributing a modest but accelerating portion of the market as companion‑diagnostic testing becomes routine. Together, these types delineate the product mix that underpins the overall market size.
